ALEXION PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - February 8, 2018

Attached files

file filename
EX-32.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 906 - ALEXION PHARMACEUTICALS, INC.alxnex32212312017.htm
EX-32.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 906 - ALEXION PHARMACEUTICALS, INC.alxnex32112312017.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - ALEXION PHARMACEUTICALS, INC.alxnex31212312017.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO SECTION 302 - ALEXION PHARMACEUTICALS, INC.alxnex31112312017.htm
EX-21.1 - SUBSIDIARIES OF ALEXION PHARMACEUTICALS, INC. - ALEXION PHARMACEUTICALS, INC.alxnex21112312017.htm
EX-10.39 - FORM OF 2017 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT FOR NON-US PARTICIPA - ALEXION PHARMACEUTICALS, INC.alxnex103912312017.htm
EX-10.38 - FORM OF 2017 INCENTIVE PLAN GLOBAL STOCK OPTION AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex103812312017.htm
EX-10.37 - FORM OF 2017 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT FOR FRENCH PARTICIPA - ALEXION PHARMACEUTICALS, INC.alxnex103712312017.htm
EX-10.36 - 2017 INCENTIVE PLAN RULES FOR AWARDS GRANTED TO PARTICIPANTS IN FRANCE - ALEXION PHARMACEUTICALS, INC.alxnex103612312017.htm
EX-10.35 - FORM OF 2017 INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT (R&D UNITS) - ALEXION PHARMACEUTICALS, INC.alxnex103512312017.htm
EX-10.34 - FORM OF 2017 INCENTIVE PLAN PERFORMANCE STOCK UNIT AGREEMENT (TSR) - ALEXION PHARMACEUTICALS, INC.alxnex103412312017.htm
EX-10.33 - FORM OF 2017 INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex103312312017.htm
EX-10.32 - FORM OF 2017 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex103212312017.htm
EX-10.6 - EMPLOYMENT AGREEMENT - ALEXION PHARMACEUTICALS, INC.alxnex10612312017.htm
10-K - FORM 10-K - ALEXION PHARMACEUTICALS, INC.alxn10k12312017.htm


Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-217905, 333-205379, 333-146319, 333-139600, 333-123212 and 333-153612) of Alexion Pharmaceuticals, Inc. of our report dated February 8, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
Hartford, Connecticut
February 8, 2018



ALEXION PHARMACEUTICALS, INC. Reports